ABCB11 p.Ala570Thr
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 17181454
[PubMed]
Sakurai A et al: "Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump."
No.
Sentence
Comment
123
[40] rs1156869 14 1674 G→C Gln558His - [102] - 14 1708 G→A Ala570Thr BRIC2 [45] - 14 1723 C→T Arg575X PFIC2 [35,46,47] rs11568367 15 1772 A→G Asn591Ser ICP [39,102] rs11568370 15 1774 G→C Glu592Gln - [102] - 15 1779 T→A/G Ser593Arg PFIC2?
X
ABCB11 p.Ala570Thr 17181454:123:73
status: NEW
PMID: 17855769
[PubMed]
Lam P et al: "Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases."
No.
Sentence
Comment
9
Therefore we compared the effect of two PFIC2 mutations (D482G, E297G) with two BRIC2 mutations (A570T and R1050C) and one ICP mutation (N591S) with regard to the subcellular localization, maturation, and function of the rat Bsep protein.
X
ABCB11 p.Ala570Thr 17855769:9:97
status: NEW11 Mutant proteins were expressed at reduced levels on the plasma membrane of transfected HEK293 cells compared with wild-type (WT) Bsep in the following order: WT Ͼ N591S Ͼ R1050C ϳ A570T ϳ E297G ϾϾ D482G.
X
ABCB11 p.Ala570Thr 17855769:11:198
status: NEW45 All point mutations (D482G, E297G, A570T, R1050C, N591S) were introduced with the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA).
X
ABCB11 p.Ala570Thr 17855769:45:35
status: NEW64 PFIC2 (D482G, E297G), BRIC2 (A570T, R1050C), and ICP (N591S) mutations that are investigated in this study are indicated in italics.
X
ABCB11 p.Ala570Thr 17855769:64:29
status: NEW94 Sf9 cells infected with recombinant virus (mock, WT, D482G, E297G, A570T, R1050C, and N591S) were harvested, and cell membranes were prepared as described previously (23).
X
ABCB11 p.Ala570Thr 17855769:94:67
status: NEW107 The subcellular distributions of D482G, E297G, A570T, R1050C, and N591S were examined first because intracellular accumulation of misfolded proteins has been shown for many diseases.
X
ABCB11 p.Ala570Thr 17855769:107:47
status: NEW118 The level of cell surface expression of Bsep protein was quantitated by densitometry and determined to be in the following order: WT (100%) Ͼ N591S (75.6 Ϯ 15.6%) Ͼ E297G (38.5 Ϯ 12.6%) ϳ R1050C (35.6 Ϯ 14.5%) ϳ A570T (29.5 Ϯ 8.8%) ϾϾ D482G (5.7 Ϯ 2.3%).
X
ABCB11 p.Ala570Thr 17855769:118:254
status: NEW120 The total expression (cell surface and intracellular proteins) also showed changes similar to those in cell surface expression: WT (100%) Ͼ N591S (73.5 Ϯ 4.3%) Ͼ E297G (33.7 Ϯ 20.4%) ϳ R1050C (26.7 Ϯ 16.0%) ϳ A570T (11.9 Ϯ 5.2%) ϾϾ D482G (2.5 Ϯ 2.0%) (Fig. 4B).
X
ABCB11 p.Ala570Thr 17855769:120:251
status: NEW150 The membrane vesicles expressing D482G, A570T, R1050C, or N591S showed similar levels of taurocholate uptake compared with WT Bsep.
X
ABCB11 p.Ala570Thr 17855769:150:40
status: NEW155 Cells were transiently transfected with pEGFPN1 (control), rat Bsep-GFP [wild type (WT)], D482G-GFP, E297G-GFP, A570T-GFP, R1050C-GFP, and N591S-GFP constructs.
X
ABCB11 p.Ala570Thr 17855769:155:112
status: NEW164 A PFIC2 mutation (D482G) is highly unstable (ϳ5% of WT), while the BRIC2 variants A570T and R1050C are expressed at the plasma membrane at intermediate levels (ϳ25% of WT).
X
ABCB11 p.Ala570Thr 17855769:164:88
status: NEW169 Cells were transfected with rat Bsep-GFP (WT), D482G-GFP, E297G-GFP, A570T-GFP, R1050C-GFP, and N591S-GFP constructs and were examined for GFP by confocal laser microscopy.
X
ABCB11 p.Ala570Thr 17855769:169:69
status: NEW171 D482G, E297G, A570T, and R1050C mutants partially colocalized with recycling endosome marker Rab11.
X
ABCB11 p.Ala570Thr 17855769:171:14
status: NEW176 D4, D482G; E2, E297G; A5, A570T; R10, R1050C; N5, N591S.
X
ABCB11 p.Ala570Thr 17855769:176:26
status: NEW183 P Ͻ 0.05, D482G, E297G, A570T, R1050C, and N591S compared with WT control.
X
ABCB11 p.Ala570Thr 17855769:183:30
status: NEW229 A: immunoblot of the isolated Sf9 cell membrane proteins with anti-Bsep polyclonal antibody: GFP control expressed in HEK293 cells, WT expressed in HEK293 cells, rat liver homogenate (L), pFastBac1-Gus control (C), wild type (WT), D482G (D4), E297G (E2), A570T (A5), R1050C (R10), N591S (N5).
X
ABCB11 p.Ala570Thr 17855769:229:255
status: NEW231 B: TCA (200 M) stimulates and orthovanadate inhibits ATPase activity in membrane vesicles containing comparable levels of WT or D482G, E297G, A570T, R1050C, and N591S mutant Bsep.
X
ABCB11 p.Ala570Thr 17855769:231:150
status: NEW
PMID: 17947449
[PubMed]
Kagawa T et al: "Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells."
No.
Sentence
Comment
13
The taurocholate transport activity was approximately half of the wild-type (WT) in BRIC2 mutants (A570T and R1050C), was substantially less in two PFIC2 mutants (D482G and E297G), and was almost abolished in six other PFIC2 mutants (K461E, G982R, R1153C, R1268Q, 3767-3768insC, and R1057X).
X
ABCB11 p.Ala570Thr 17947449:13:99
status: NEW19 In conclusion, taurocholate transport function was impaired in proportion to rapid degradation of Bsep protein in the mutants, which were aligned in the following order: A570T and R1050C Ͼ D482G Ͼ E297G Ͼ K461E, G982R, R1153C, R1268Q, 3767-3768insC, and R1057X.
X
ABCB11 p.Ala570Thr 17947449:19:170
status: NEW139 The positions of 8 PFIC2 mutations (E297G, K461E, D482G, G982R, R1057C, R1153C, 3767-3768insC, and R1268Q) and 2 BRIC2 mutations (A570T and R1050C) are indicated by ଝ and ଙ, respectively.
X
ABCB11 p.Ala570Thr 17947449:139:130
status: NEW166 In contrast, two BRIC2 mutants exhibited considerable transport activity (A570T: 52.2 Ϯ 13.0%, R1050C: 58.7 Ϯ 9.9% of the WT).
X
ABCB11 p.Ala570Thr 17947449:166:74
status: NEW170 A570T and R1050C Fig. 2.
X
ABCB11 p.Ala570Thr 17947449:170:0
status: NEW181 mRNA expression levels examined in MDCK II cells expressing these mutants except for A570T were slightly higher than those with WT, but the difference was not statistically significant (Fig. 6D).
X
ABCB11 p.Ala570Thr 17947449:181:85
status: NEW184 Subcellular distribution study revealed that E297G, R1057X, A570T, and R1050C mutants were predominantly located along the apical membrane, whereas the other PFIC2 mutants (K461E, G982R, R1153C, R1268Q, and 3767-3768insC) remained intracellular (Fig. 7).
X
ABCB11 p.Ala570Thr 17947449:184:60
status: NEW185 In summary, BRIC2 mutants (A570T and R1050C) were expressed substantially, trafficked correctly, and maintained half of transport activity.
X
ABCB11 p.Ala570Thr 17947449:185:27
status: NEW286 TC transport activity was 50-60% in BRIC2 mutants (A570T and R1050C) and 0-30% in PFIC2 mutants.
X
ABCB11 p.Ala570Thr 17947449:286:51
status: NEW290 From the view of maintenance of TC transport activity, the mutants could be aligned in the following order: A570T and R1050C Ͼ D482G Ͼ E297G Ͼ K461E, G982R, R1153C, R1268Q, 3767-3768insC, and R1057X.
X
ABCB11 p.Ala570Thr 17947449:290:108
status: NEW
No.
Sentence
Comment
194
Even more subtle mutations of ABCB11 were described in patients with an intermittent form of disease (BRIC2; see below), these mutations include E186G, A570T, T923P, A926P, R1050C, R1128H, V444A, and E297G.
X
ABCB11 p.Ala570Thr 18376240:194:152
status: NEW
PMID: 19101985
[PubMed]
Byrne JA et al: "Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing."
No.
Sentence
Comment
8
Taurocholate transport by two assessed mutants, N490D and A570T, was reduced compared with wild-type.
X
ABCB11 p.Ala570Thr 19101985:8:58
status: NEW67 ABCB11 Missense Mutations and SNPs Functionally Analyzed in This Study Exon Nucleotide Change Predicted Protein Effect Location in Protein Associated Phenotype Prevalence or Frequency* Any Defect(s) Identified Reference 4 c.149TϾC L50S NH2 term PFIC 1 family (het) Immature protein 31 5 c.270TϾC F90F EC1 SNP 2.7%-7.7% 43, 45 6 c.403GϾA E135K EC1 BRIC 1 family (het) Reduced levels of mature protein † 6 c.409GϾA E137K EC1 BRIC / ICP 1 family (het) Immature protein ‡ 7 c.500CϾT A167V TM2 PFIC 1 family (hom) Mild exon skipping beta 7 c.557AϾG E186G IC1 BRIC 2 families (both het) Moderate exon skipping; greatly reduced levels of mature protein 8, 37 7 c.580TϾC S194P IC1 SNP-PSC 1.1% 43 7 c.593TϾC L198P IC1 BRIC / ICP / DC 1 family (het) Greatly reduced levels of mature protein # 8 c.713GϾT G238V EC2 PFIC 1 family (hom) 29 8 c.725CϾT T242I TM4 PFIC 1 family (het) 31 8 c.779GϾA G260D TM4 SNP-PBC 0.8% 43 9 c.850GϾC V284L IC2 PFIC 1 family (het) No protein 28 9 c.851TϾC V284A IC2 SNP 0.5% Increased levels of mature protein 43, 45† 9 c.889GϾA E297K IC2 Prolonged NNH 1 family (het) Moderate differential splicing; immature protein ‡ 9 c. 890AϾG E297G IC2 PFIC, BRIC PFIC, 45 families (14 hom, 31 het) BRIC, 4 families (2 hom, 2 het) Greatly reduced levels of mature protein 7, 8, 12, 29-32, 35 10 c.936GϾT Q312H IC2 PFIC 1 family (het) ‡ 10 c.937CϾA R313S IC2 PFIC 1 family (het) 31 10 c.957AϾG G319G TM5 SNP 1.5 - 7.5% Mild exon skipping 42, 43, 45 10 c.980GϾA G327E TM5 PFIC 1 family (het) 31 10 c.1007GϾC C336S TM5 PFIC 1 family (het) 29 11 c.1168GϾC A390P NBF PFIC, BRIC 2 families (both het) Immature protein 31; # 12 c.1129GϾA G410D NBF PFIC 1 family (het) 31 12 c.1238TϾG L413W NBF PFIC 1 family (het) Greatly reduced levels of mature protein 31 12 c.1244GϾA R415Q NBF SNP-ICP 1.3% 42 12 c.1295GϾC R432T NBF BRIC 1 family (het) Reduced levels of mature protein 12 13 c.1331CϾT A444V NBF SNP, ICP, CC, DC, BRIC 43-60% Increased levels of mature protein 8, 28, 37, 39-45 13 c.1381AϾG K461E WA PFIC 1 family (hom) Immature protein 7 13 c.1388CϾT T463I WA PFIC 1 family (het) Mild exon skipping 31 13 c.1396CϾA Q466K Adj WA PFIC 1 family (het) 31 13 c.1409GϾA R470Q Adj WA PFIC 2 families (1 het, 1 consanguineous) Immature protein 31 14 c.1442TϾA V481E NBF1 PFIC 1 family (het) 31 14 c.1445AϾG D482G NBF1 PFIC 22 families (16 het, 6 hom) Severe differential splicing; immature protein 7, 30-32 14 c.1468AϾG N490D NBF1 PFIC 1 family (het) Greatly reduced levels of mature protein; reduction in bile salt transport 31 14 c.1493TϾC I498T NBF1 PFIC / BRIC 1 family (het) 38 14 c.1530CϾA T510T NBF1 SNP-PBC 0.7% 43 14 c.1535TϾC I512T NBF1 PFIC 1 family (het) 31 14 c.1544AϾC N515T NBF1 PFIC 1 family (het) 31, 32 14 c.1440GϾA R517H NBF1 PFIC 1 family (het) No protein 31, 32 14 c.1605CϾT A535A NBF1 SNP 0.3% Slightly reduced levels mature protein 39, 45 14 c.1621AϾC I541L NBF1 PFIC 3 families (1 het, 2 consanguineous) No protein 31-33 15 c.1643TϾA F548Y Adj ABCm PFIC 1 family (het) 31, 32 15 c.1685GϾA G562D ABCm PFIC 1 family (het) 31 15 c.1708GϾA A570T Adj ABCm/WB PFIC, BRIC PFIC, 1 family Greatly reduced levels of mature protein; reduction in bile salt transport 8, 31 Table 1.
X
ABCB11 p.Ala570Thr 19101985:67:3349
status: NEW142 The mutations N490D (c.1468AϾG; Fig. 5A), R1128H (c.3383GϾA; Fig. 5B), E297G (c. 890AϾG), and A570T (c.1708GϾA; Fig. 5D), and E186G (c.557AϾG; Fig. 5E) resulted in significantly reduced levels of mature protein, and the L198P (c.593TϾC) variant was barely detectable (Fig. 5C).
X
ABCB11 p.Ala570Thr 19101985:142:112
status: NEW154 The following mutations showed an enrichment of mature BSEP: R1153H (c.3458GϾA; Fig. 6B), R1128C (c.3382CϾT), R1128H (c.3383GϾA), R1231Q (c.3692GϾA), R1050C (c.3148CϾT; Fig. 6C) and R1268Q (c.3892GϾA), A570T (c.1708GϾA), and E297K (c.889GϾA; Fig. 6D).
X
ABCB11 p.Ala570Thr 19101985:154:238
status: NEW163 Wild-type and variant ABCB11 baculoviruses with the mutations N490D (c.1468AϾG) and A570T (c.1708GϾA) were created, and, after infection of Hi5 insect cells, inside-out membrane vesicles were prepared to perform taurocholate transport assays.3 The mutant N490D was chosen because it generated a mature form of BSEP, although in reduced abundance (Fig. 5A), and because the associated disease was severe,30 whereas A570T was amenable to glycerol and reduced temperature: these enhanced the abundance of a mature form of BSEP (Fig. 6D).
X
ABCB11 p.Ala570Thr 19101985:163:90
status: NEWX
ABCB11 p.Ala570Thr 19101985:163:426
status: NEW167 The N490D mutation was associated with 27% and the A570T mutation with 60% of normal activity.
X
ABCB11 p.Ala570Thr 19101985:167:51
status: NEW174 (A) Baculoviruses were created that contained either the wild-type ABCB11 cDNA, that encoding N490D (c.1468AϾG), or A570T (c.1708GϾA) and were used, along with a mock baculovirus, to transduce Hi5 insect cells.
X
ABCB11 p.Ala570Thr 19101985:174:122
status: NEW219 These include the PFIC-associated mutations E297G (c.890AϾG; Fig. 6A), R1128C (c.3382CϾT) and R1231Q (c.3692GϾA; Fig. 6C), and R1268Q (c.3892GϾA; Fig. 6.d), the BRIC-associated mutations R1128H (c.3383GϾA) and R1050C (c.3148CϾT; Fig. 6C), and E297K (c.889GϾA; Fig. 6D), as well as A570T (c.1708GϾA), which can be associated with either form of disease.
X
ABCB11 p.Ala570Thr 19101985:219:323
status: NEW226 Two mutations, N490D (c.1468AϾG) and A570T (c.1708GϾA), were expressed in insect cells and then assessed for their ability to transport taurocholate (Fig. 7A, B).
X
ABCB11 p.Ala570Thr 19101985:226:43
status: NEW228 Despite equal expression of both mutants in these cells, N490D had only 27% and A570T had 60% of the activity of the wild-type protein, respectively.
X
ABCB11 p.Ala570Thr 19101985:228:82
status: NEW230 A570T was identified on both alleles in a patient with BRIC who required a partial external biliary diversion to treat progressive cholestasis at the age of 18 years.8 Both N490D and A570T are situated in the first NBF of BSEP; N490D is conserved across the MDR family, whereas A570T is also conserved in MDR-associated protein 2 and CFTR.
X
ABCB11 p.Ala570Thr 19101985:230:0
status: NEWX
ABCB11 p.Ala570Thr 19101985:230:183
status: NEWX
ABCB11 p.Ala570Thr 19101985:230:278
status: NEW231 However, the substitution N490D is more functionally detrimental and apparently more clinically severe than A570T.
X
ABCB11 p.Ala570Thr 19101985:231:108
status: NEW232 The recent expression of rat Bsep with A570T in MDCK cells gave comparable results to our study with respect to levels of mature protein.14 These authors attributed an approximately 50% reduction of taurocholate transport solely to reduced BSEP protein expression levels, whereas our data suggest an additional defect in transport activity.
X
ABCB11 p.Ala570Thr 19101985:232:39
status: NEW
PMID: 21490445
[PubMed]
Evason K et al: "Morphologic findings in progressive familial intrahepatic cholestasis 2 (PFIC2): correlation with genetic and immunohistochemical studies."
No.
Sentence
Comment
143
Immunohistochemical Findings and Genetic Abnormalities Patient BSEP Mutation Type of Mutation(s) 1 Absent c.890A>G (p.E297G)* Missense5,7,10,13,16,19,20 2 Absent c.1723C>T (p.R575X) Nonsense7,19,20 c.2178+1G>T Noncoding region20 3 Present c.1708G>A (p.A570T) Missense20 c.3634G>T (p.V1212F) Missense, predicted deleterious 4 Absent c.3164T>C (p.L1055P)* Missense, predicted deleterious 5 Absent c.3692G>A (p.R1231Q) Missense20 c.2296G>A (p.G766R) Missense20 6 Absent c.2782C>T (p.R928X) Nonsense13 c.3268C>T (p.R1090X) Nonsense5,7,13 7 Present c.3347G>A (p.G1116E) Missense, predicted deleterious IVS 23-8 G-A Noncoding region 8 Absent IVS 16-8 T>Gw Noncoding region10 9 Absent c.2944G>A (p.G982R) Missense5,7,19,20 c.2296G>A (p.G766R) Missense20 10 Absent c.2944G>A (p.G982R) Missense5,7,19,20 c.2296G>A (p.G766R) Missense20 11 Absent c.319T>C (p.C107R) Missense, predicted deleterious c.611+4A>G Noncoding region 12 Absent c.1723C>T (p.R575X) Nonsense7,19,20 c.2178+1G>T Noncoding region20 *Homozygous.
X
ABCB11 p.Ala570Thr 21490445:143:252
status: NEW
PMID: 20799350
[PubMed]
Kelly L et al: "Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains."
No.
Sentence
Comment
50
Disease-associated nsSNPs at Three Structural Hotspots in Human ABC Transporter NBDs Gene Disease Position ARA motif ABCB11 BRIC2 A570T ABCD1 X-ALD A616V CFTR CF A559T ABCC6 PXE R765Q ABCC8 HHF1 R841G ABCC8 HHF1 R1493Q ABCC8 HHF1 R1493W ABCD1 X-ALD R617C ABCD1 X-ALD R617G ABCD1 X-ALD R617H CFTR CF R560K CFTR CF R560S CFTR CF R560T ABCA1 HDLD1 A1046D ABCB4 ICP A546D C-loop 1 motif ABCC8 HHF1 D1471H ABCC8 HHF1 D1471N CFTR CBAVD G544V ABCC8 HHF1 G1478R C-loop2 motif ABCA4 STGD1 H2128R ABCC8 HHF1 K889T ABCD1 X-ALD R660P ABCD1 X-ALD R660W ABCA1 HDLD2 M1091T ABCA4 STGD1 E2131K ABCA12 LI2 E1539K ABCA4 STGD1 and CORD3 E1122K CFTR CF L610S ABCC8 HHF1 L1543P ABCA1 Colorectal cancer sample; somatic mutation A2109T ABCC9 CMD1O A1513T ABCD1 X-ALD H667D CFTR CF A613T ABCA1 HDLD2 D1099Y ABCD1 X-ALD T668I CFTR CF D614G ABCA4 STGD1 R2139W ABCA4 STGD1 R1129C ABCA4 ARMD2, STGD1, and FFM R1129L Disease abbreviations are as follows: BRIC2, benign recurrent intrahepatic cholestasis type 2; X-ALD, X-linked adrenoleukodystrophy; CF, cystic fibrosis; PXE, Pseudoxanthoma elasticum; HHF1, familial hyperinsulinemic hypoglycemia-1; HDLD1, high density lipoprotein deficiency type 1; ICP, intrahepatic cholestasis of pregnancy; CBAVD, congenital bilateral absence of the vas deferens; STGD1, Stargardt disease type 1; HDLD2, high density lipoprotein deficiency type 2; LI2, ichthyosis lamellar type 2; CORD3, cone-rod dystrophy type 3; CMD1O, cardiomyopathy dilated type 1O; ARMD2, age-related macular degeneration type 2; FFM, fundus flavimaculatus.
X
ABCB11 p.Ala570Thr 20799350:50:130
status: NEW
PMID: 18395098
[PubMed]
Strautnieks SS et al: "Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families."
No.
Sentence
Comment
150
Missense Mutations in ABCB11 Nucleotide change Predicted effect Exon CpG site Location Change in: Size Charge Hyd/Pol Shape c.149Tb0e;C p.Leu50Ser 4 No NH2 term Y Y Y c.470Ab0e;G p.Tyr157Cys 6 No TM2 Y Y Y c.725Cb0e;T p.Thr242Ile 8 No TM4 Y Y c.890Ab0e;G p.Glu297Gly 9 No IC2 Y Y Y c.908Gb0e;A p.Arg303Lys 9 No IC2 c.937Cb0e;A p.Arg313Ser 10 Yes IC2 Y Y Y Y c.980Gb0e;A p.Gly327Glu 10 No TM5 Y Y Y c.1168Gb0e;C p.Ala390Pro 11 No TM/NBF Y c.1229Gb0e;A p.Gly410Asp 12 No TM/NBF Y Y c.1238Tb0e;G p.Leu413Trp 12 No TM/NBF c.1388Cb0e;T p.Thr463Ile 13 No Adj Walker A Y Y Y c.1396Cb0e;A p.Gln466Lys 13 No Adj Walker A Y c.1409Gb0e;A p.Arg470Gln 13 Yes Adj Walker A Y c.1415Ab0e;G p.Tyr472Cys 13 No Adj Walker A Y Y Y c.1442Tb0e;A p.Val481Glu 14 No NBF1 Y Y Y c.1445Ab0e;G p.Asp482Gly 14 No NBF1 Y Y c.1460Gb0e;C p.Arg487Pro 14 Yes NBF1 Y Y Y Y c.1468Ab0e;G p.Asn490Asp 14 No NBF1 Y c.1535Tb0e;C p.Ile512Thr 14 No NBF1 Y Y Y c.1544Ab0e;C p.Asn515Thr 14 No NBF1 Y Y c.1550Gb0e;A p.Arg517His 14 Yes NBF1 Y Y c.1621Ab0e;C p.Ile541Leu 14 No NBF1 c.1622Tb0e;C p.Ile541Thr 14 No NBF1 Y Y Y c.1643Tb0e;A p.Phe548Tyr 15 No Adj ABC c.1685Gb0e;A p.Gly562Asp 15 No ABC Y Y c.1708Gb0e;A p.Ala570Thr 15 Yes ABC/Walker B Y c.1763Cb0e;T p.Ala588Val 15 No Adj Walker B Y c.2272Gb0e;C p.Gly758Arg 19 No NBF/TM Y Y Y c.2296Gb0e;A p.Gly766Arg 19 Yes TM7 Y Y Y c.2494Cb0e;T p.Arg832Cys 21 Yes IC3 Y Y Y Y c.2576Cb0e;G p.Thr859Arg 21 No IC3 Y Y Y Y c.2842Cb0e;T p.Arg948Cys 23 Yes IC4 Y Y Y Y c.2935Ab0e;G p.Asn979Asp 23 No TM11 Y c.2944Gb0e;A p.Gly982Arg 23 Yes TM11 Y Y Y c.3086Cb0e;A p.Thr1029Lys 24 No TM12 Y Y Y Y c.3329Cb0e;A p.Ala1110Glu 25 Yes Adj Walker A Y Y Y c.3382Cb0e;T p.Arg1128Cys 25 Yes Adj Walker A Y Y Y Y c.3457Cb0e;T p.Arg1153Cys 26 Yes NBF2 Y Y Y Y c.3458Gb0e;A p.Arg1153His 26 Yes NBF2 Y Y c.3460Tb0e;C p.Ser1154Pro 26 No NBF2 Y c.3628Ab0e;C p.Thr1210Pro 27 No Adj ABC Y c.3691Cb0e;T p.Arg1231Trp 27 Yes ABC/Walker B Y Y c.3692Gb0e;A p.Arg1231Gln 27 Yes ABC/Walker B Y c.3724Cb0e;A p.Leu1242Ile 27 No Walker B c.3892Gb0e;A p.Gly1298Arg 28 No NBF2 Y Y Y NOTE.
X
ABCB11 p.Ala570Thr 18395098:150:1248
status: NEW222 BSEP deficiency represents a phenotypic continuum between progressive early-onset1 disease and remitting, and late-onset, phenotypes.3-7 Eleven different mutations have been reported in BSEP deficiency disease clinically assessed as intermediate6 or mild in severity.4,5,7 Three of these, E297G, A570T, and c.2178af9;1Gb0e;A, have also been found in progressive familial intrahepatic cholestasis.
X
ABCB11 p.Ala570Thr 18395098:222:296
status: NEW
No.
Sentence
Comment
182
Mutations such as p.E186G, p.E297G, p.R432T, p.A570T, p.T923P, p.A926P, p.G1004D, p.R1050C and p.R1128H have been described in BRIC-2 patients [137,140-142] (Table 1).
X
ABCB11 p.Ala570Thr 22795478:182:47
status: NEW185 PFIC BRIC/NFC ICP Other liver diseases Genetic variants without disease association Missense mutations M1V C336S D549V L1055P E135K E137K T87R V43I S701P G19R W342G G556R C1083Y E137K L198P M123T S56L L712L L50S A382G G562D A1110E E186G E297G S194P Q121K A865D M62K R387H A570T S1114R L198P R415Q L198P R128H A865G C68Y A390P L581F G1116E E297G V444A G260D I206V S874P C107R G410D A588V G1116F G374S D482G E297K V284A I939M I112T L413W S593R G1116R A390P N591S V444A G295C R958Q W114R I420T I627T S1120N R432T T655I T510T G295R F959C Y157C D440E E636G R1128C V444A T655I G295S F959V A167T G455E R698C S1144R I498T D676Y R299K T965S A167V K461E S699P R1153C A570T P710P R303K F971L I182K T463I E709K R1153H T586I L827I L339V F971Y M183T Q466K G758R S1154P G648V G855R H423R L1006F M183V R470Q G766R N1173D T655I E1186K V444A N1009H G188W Y472C Y818F T1210P T923P V444D K1145N M217R V481E R832C N1211D A926P V444G I1183T R223C D482G R832H V1212F R948C A459V S226L R487H T859R R1231Q G1004D I468I G238V R487P A865V R1231W R1050C R487L T242I N490D Q869P L1242I G1116R Q546K A257G I498T G877R D1243G R1128H Q558H V284L G499E S901R R1268Q L1197G E592Q E297G I512T R948C A1283V R1231Q V597M R303G N515T N979D G1292V R616G R303K R517H G982R G1298R T619A Q312H F540L G1004D M677L R313S I541L T1029K M677V G327E I541T G1032R R696Q W330R F548Y A1044P R698H Nonsense mutations (premature stop-codons) S25X Y472X Y772X R1090X E96X W493X Q791X V1147X W330X R520X R928X Q1215X Y354X I528X Y1041X R1235X R415X R575X R1057X E1302X R470X Q702X Q1058X Table 1 (Continued) PFIC BRIC/NFC ICP Other liver diseases Genetic variants without disease association Splice site mutations 76 + 3G > T 908 + 1delG 2178 + 1G > T 3057-2A > G Q159Q 77-1G > C 908 + 1G > T 2179-2A > G 3213 + 1delG Q361Q 99-1G > T 908 + 1G > A 2343 + 1G > T 3213 + 4A > G 150 + 3A > C 1435-13 -8del 2343 + 2T > C 3213 + 5G > A 390-1G > A 2012-8T > G 2611-2A > T 611 + 1G > A 2178 + 1G > A R1001R Deletions/insertions/frame shifts Q101Dfs8X L380Wfs18X G648Vfs5X Q1058Hfs38X F959Hfs1X T127Hfs6X A382 A388del K700Sfs12X I1061Vfs34X F959Gfs48X N199Ifs14X P456Pfs24X T919del L1165del L232Cfs9X H484Rfs5X K930Efs92X A1192Efs50X R303Sfs17X I528Sfs21X K930Efs79X T1256Tfs40X V368Rfs27X I610Qfs45X K969 K972del Synonymous variants without disease association R33R F90F L232L I416I G557G I876I A1028A K1145K D36D I134I Y269Y G418G V597V G937G K1070K R52R S136S Q312Q F427F A804A Y981Y T1086T D58D V195V G319G E395E A535A G817G G1004G A1110A The overview shows ࣈ 290 known variants of BSEP on the protein level, except splice site mutations, which are shown on cDNA level.
X
ABCB11 p.Ala570Thr 22795478:185:272
status: NEWX
ABCB11 p.Ala570Thr 22795478:185:657
status: NEW
PMID: 23685087
[PubMed]
Soroka CJ et al: "Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations."
No.
Sentence
Comment
145
We examined differences in protein maturation, plasma membrane localization and transport activity in mutants of rat Bsep representing two PFIC2 (D482G and E297G), two BRIC2 (A570T and R1050C) and one ICP (N591) mutation (Lam et al., 2007).
X
ABCB11 p.Ala570Thr 23685087:145:175
status: NEW
PMID: 23722250
[PubMed]
Kagawa T et al: "Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells."
No.
Sentence
Comment
11
UDCA significantly increased the activity of Bsep with a benign recurrent intrahepatic cholestasis 2 mutation (A570T) but did not affect Bsep with a progressive familial intrahepatic cholestasis 2 mutation (G982R or D482G).
X
ABCB11 p.Ala570Thr 23722250:11:111
status: NEW88 MDCK-Ntcp cells were transfected with an expression vector that contained mutated Bsep, including any of a PFIC2 mutation (G982R or D482G) and a BRIC2 mutation (A570T) [11].
X
ABCB11 p.Ala570Thr 23722250:88:161
status: NEW90 Basal Bsep activity was slightly lower in the A570T mutant (80.6 % of the wild-type Bsep activity) and much lower in the G982R (15.3 %) and D482G (18.8 %) mutants compared with that in wild-type Bsep (Fig. 6).
X
ABCB11 p.Ala570Thr 23722250:90:46
status: NEW91 UDCA activated the A570T mutant by 1.3-fold.
X
ABCB11 p.Ala570Thr 23722250:91:19
status: NEW163 The inability of TUDCA to stimulate Bsep activity was unexpected because this molecule has been reported to 0 50 100 150 200 wild-type A570T G982R D482G UDCA - + - + - + - + * ** Bsep activity (%) Fig. 6 The effect of UDCA on mutant Bsep activity.
X
ABCB11 p.Ala570Thr 23722250:163:135
status: NEW164 MDCK II cells stably expressing wild-type or mutant (A570T, G982R, or D482G) Bsep were incubated in the presence or absence of UDCA (100 lM) for 24 h after preincubation with sodium butyrate (5 mM) for 24 h. Thereafter, these cells were incubated for 1 h at 37 &#b0;C with [3 H]-TC (1 lM) and cold TC (10 lM) in the lower compartment. The intracellular accumulation and transcellular flux of TC were calculated on the basis of the radioactivity in the total cells and apical medium, respectively. Bsep activity was determined by the permeability-surface area product for TC transport across the apical membrane (PSapical), which was calculated as (rate of transcellular TC flux)/(intracellular TC concentration).
X
ABCB11 p.Ala570Thr 23722250:164:53
status: NEW176 In contrast, the A570T mutant, which causes BRIC2, showed considerable Bsep activity (*70 %), in agreement with a previous report [11].
X
ABCB11 p.Ala570Thr 23722250:176:17
status: NEW
No.
Sentence
Comment
100
For example, the two 'BRIC-2 mutations` p.A570T and p.R1050C had lower expression levels than the 'ICP mutation` p.N591S, but higher expression levels as compared to the PFIC-2 mutations p.D482G and p.E297G [59].
X
ABCB11 p.Ala570Thr 25027376:100:42
status: NEW137 BSEP/Bsep NTCP ASBT Exon skipping E186G G1116R G319G R1128C T463I R1128H A926P E1186K A1028Aa R1231W A1110E Aberrant splicing E297K R1153H R832C S1154P S1144R No splice product T586I R1231Q Reduced plasma membrane expression E135K A570T I223T E297Gb N591Sb V444A R1050C Intracellular retention Y818F G982R Reduced or absent bile salt transport A570T R432T A64T K314E V98Ic M264V I206V Q558H I223T C144Y P290S E297Gb N591Sb S267F L243P G374S E1186K I279T T262M a A1028A induces significant exon skipping in vitro but probably not in vivo (unpublished data; Dro &#a8;ge, Ha &#a8;ussinger, Kubitz).
X
ABCB11 p.Ala570Thr 25027376:137:231
status: NEWX
ABCB11 p.Ala570Thr 25027376:137:344
status: NEW